Top Tweets for #mcspc
📢 @ASCO #ASCO26: TALAPRO-3 met its primary end point in HRR-altered #mCSPC.
Talazoparib + enzalutamide reduced the risk of radiographic progression or death by 52% vs enzalutamide alone and delivered benefit across BRCA and non-BRCA HRR subgroups.
@neerajaiims @huntsmancancer #medtwitter #oncology #pcsm
https://t.co/kSKuKys2A4
Major adverse cardiovascular events in ARPI-treated patients with #mCSPC. Presentation by Linden Huhmann @DeptVetAffairs. #ASCO26 written coverage by @zklaassen_md @GACancerCenter > https://t.co/FR06kvs0Au @ASCO
Validation of PSA decline among the Latin American Subgroup of #LIBERTAS: A phase 3 study of apalutamide + continuous vs intermittent ADT in #mCSPC. Presentation by Andrea Juliana Gomes. #ASCO26 written coverage by @zklaassen_md > https://t.co/Bf10mYlzni @ASCO
#TALAPRO3: Talazoparib + enzalutamide compared with placebo + enzalutamide for the treatment of patients with #mCSPC harboring HRR gene alterations. Presentation by @neerajaiims @huntsmancancer. #ASCO26 written coverage by @chavarriagaj @PSH_Urology > https://t.co/WApw8pUD62 @ASCO
📢#ASCO26 TALAPRO-3 met its primary endpoint in HRR-altered #mCSPC, with talazoparib + enzalutamide significantly improving rPFS vs enzalutamide alone.
Key findings:
🔹 rPFS HR 0.48 (p<0.0001)
🔹 Benefit observed in both:
• BRCA-altered disease: HR 0.37
• Non-BRCA HRR alterations: HR 0.57
Additional signals:
🔹 Time to PSA progression HR 0.51
🔹 Delayed subsequent therapy HR 0.51
🔹 OS trend favored the combination (HR 0.77)
Importantly, despite higher rates of anemia and hematologic toxicity, PROs remained largely preserved between arms.
@UroToday @ASCO
#ASCO26 @neerajaiims Could #TALAPRO3 establish a new SOC for HRR-mutated #mCSPC Talazoparib + enzalutamide reduced the risk of progression or death by 52% (HR 0.48) ATM 🥇Pending OS @urotoday @SCUColombia @achoHematoYOnco @OncoAlert @Uromigos @oncodaily @ASCO @myESMO @UroOnc
🚨 #ASCO26
**TALAPRO-3** met its primary endpoint. Adding **talazoparib** to **enzalutamide** significantly improved rPFS in patients with HRR-altered metastatic castration-sensitive prostate cancer (#mCSPC).
rPFS: HR 0.48 (52% reduction in risk of progression or death)
BRCA1/2-mutated: HR 0.37
Non-BRCA HRR alterations: HR 0.57
OS trend favored the combination (HR 0.77)
Main AEs: anemia, neutropenia, and fatigue
A practice-changing study highlighting the importance of **early genomic testing** in advanced prostate cancer.
👏 Presented by **Dr. Neeraj Agarwal**
@ASCO @OncoAlert @urotoday
#ProstateCancer #GUOnc #PrecisionOncology #PARPi #Talazoparib #Enzalutamide #HRR #BRCA #ASCO2026 #mCSPC
📌Landmark, phase III #TALAPRO3 trial in #HRRa #mCSPC:
⭕️MET primary endpoint: #talazoparib + #enzalutamide sig improved #rPFS vs ENZA alone (HR 0.48, 95% CI 0.357-0.647, p<0.0001)
▶️Benefit more prominent in BRCA-mutated (HR 0.368) but also seen in nonBRCA-mutated (HR 0.567) subgrouos.
▶️OS trend favored TALA+ENZA
▶️Safety was manageable and consistent with known profiles, though 3 MDS/2 AML
✅️These data lend support to TALA + ENZA in 1L setting for HRR altered mCSPC
#ASCO2026 @ASCO
@TiansterZhang @QianJanieQin @montypal @PGrivasMDPhD @DrChoueiri @neerajaiims @OncoAlert
@neerajaiims PhIII TALAPRO-3 of #ADT + enza +/- talazoparib in #1L HRR-mutant #mCSPC ➡️ improved rPFS in BRCA/non-BRCA-mt pts in tala arm, OS immature, G3-4 TRAEs 79% vs 41% in control, 3 cases MDS & 2 cases AML (tala arm) vs 1 case MDS/AML (control arm)
#ASCO26 @OncoAlert
Dr. Medina retrospective analysis of #CHAARTED ➡️ 26-gene spatial expression model inferred from #H&E slides identifies benefit to addition of #docetaxel to #ADT if biomarker positive in #1L #mCSPC
#ASCO26 @OncoAlert
Real-world characteristics, HRR mutation testing, treatment patterns, and outcomes of patients with #mCSPC in the US community #oncology setting. Upcoming poster presentation by Manojkumar Bupathi, MD, MS. #ASCO26 written coverage by @chavarriagaj > https://t.co/Z66P6X3Z5v
Uptake of doublet and triplet therapy for men with de novo #mCSPC - a population-based study. Presented by Paolo Zaurito, MD @SanRaffaeleMI. #AUA26 written coverage by @chavarriagaj @PSH_Urology > https://t.co/suTfGkAtj8 @AmerUrological
Mañana en el ESMO Summit Latin America 🌎
“Dupletas en mCSPC de Alto Volumen: Datos de Mundo Real para Guiar la Práctica Clínica”
Happy to share this with people I truly admire and appreciate @raymanneh
�� Bogotá | 17 Abril | 1:00 PM
@ESMO #mCSPC #ESMOSummitLA @Marco_Care_AI
Result never in doubt in #mCSPC #ProstateCancer given design
Questions should focus on short & long term toxicity. Also is sequencing (w/deferred tox) in any way inferior❓
Talazoparib/Enzalutamide Shows Improved Radiographic PFS https://t.co/IpyQdtcT1L
💡Early results from TALAPRO-3 suggest that the combination of talazoparib and enzalutamide may redefine the treatment paradigm for HRR gene-mutated #mCSPC https://t.co/AtEQZLRPPa
Impact of hospitalizations on health-related quality of life and overall survival in #mCSPC: Insights from the #ARANOTE trial. Presented by @CaPsurvivorship @DanaFarber. #GU26 written coverage by @zklaassen_md @GACancerCenter > https://t.co/Fk7TcRyC1b @ASCO
#MEVPRO-3: Phase III trial of mevrometostat + enzalutamide vs placebo + enzalutamide in #mCSPC. Presentation by @neerajaiims @huntsmancancer. #GU26 written coverage by @zklaassen_md @GACancerCenter > https://t.co/yWz8Sm9S1Q @ASCO #ASCOGU26
Safety profile of darolutamide + adt compared to enzalutamide, apalutamide, and abiraterone in #mCSPC #ProstateCancer: results from the first safety matching-adjusted indirect comparison. Presented by Neal Shore, MD, FACS @CURCMB. #GU26 written coverage by @RKSayyid @UAUrology > https://t.co/LmiyckHICi @ASCO
Real-world comparison of PSA response in #mCSPC patients treated with apalutamide without docetaxel vs darolutamide without docetaxel. Presented by @bilenma @EmoryUniversity. #GU26 written coverage by @RKSayyid @UAUrology > https://t.co/UlRZ9TsaWw @ASCO #ASCOGU26
WATCH 👀: @bilenma of @WinshipAtEmory discusses findings from a real-world analysis of apalutamide vs darolutamide in mCSPC.
See the whole video here 📽️: https://t.co/8mf2mbRu7k
#oncology #pcsm #mcspc
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.2M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
112.9M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.3M followers
NASA
@nasa
92.3M followers
Justin Bieber
@justinbieber
91.5M followers
KATY PERRY
@katyperry
89.1M followers
Taylor Swift
@taylorswift13
83M followers
Lady Gaga
@ladygaga
74.5M followers
Virat Kohli
@imvkohli
72M followers
Kim Kardashian
@kimkardashian
70.5M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
64.9M followers
Bill Gates
@billgates
64.6M followers
The Ellen Show
@theellenshow
62.4M followers
Selena Gomez
@selenagomez
62.1M followers
CNN
@cnn
61.8M followers
X
@x
60.8M followers